FREQUENTLY ASKED QUESTIONS FOR
HEALTHCARE PROVIDERS
References:
-
NDA 213872.
-
Astepro. Prescribing information. Meda Pharmaceuticals Inc; 2018.
-
US Department of Health and Human Services. Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review. November 3, 2016. Accessed April 7, 2022. https://www.fda.gov/media/100100/download
-
Astelin. Prescribing information. Meda Pharmaceuticals Inc; 2014.
-
van Bavel J, Howland WC, Amar NJ, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(5):512-518. doi:10.2500/aap.2009.30.3284
-
Watts AM, Cripps AW, West NP, Cox AJ. Modulation of allergic inflammation in the nasal mucosa of allergic rhinitis sufferers with topical pharmaceutical agents. Front Pharmacol. 2019;10:294:1-22. doi:10.3389/fphar.2019.00294
-
Flonase® Drug Facts Label. NDA205434.
-
Nasacort® Drug Facts Label. NDA020468.
-
Rhinocort® Drug Facts Label. NDA020746.
-
Shah S, Berger W, Lumry W, La Force C, Wheeler W, Sacks H. Ecacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2009:30(6):628-633. doi:10.2500/aap.2009.30.3296
-
Data on file. Bayer. MP436 CSR. Safety and tolerability.